Details

Autor(en) / Beteiligte

• Catts, Stanley V
• O'Toole, Brian I

Titel

Reducing long-term antipsychotic use: a therapeutic dead end?

Ist Teil von

• British journal of psychiatry, 2017-05, Vol.210 (5), p.368-368

Ort / Verlag

England: Cambridge University Press

Erscheinungsjahr

2017

Link zum Volltext

Quelle

Applied Social Sciences Index & Abstracts (ASSIA)

Beschreibungen/Notizen

• The clinical evidence for antipsychotic medication reducing the mortality rate at all stages of the illness is of high quality and very consistent (summarised by Tiihonen 5 ); the simple truth is that taking more patients off maintenance medication will result in more patients dying unnecessarily – the ultimate therapeutic dead end. Declaration of interest S.V.C. has received funding for acting in the role of an advisory board member, as a sponsored educational speaker, and for research projects from the following pharmaceutical companies: Janssen-Cilag Pty Ltd, Eli Lilly Australia Pty Ltd, Lundbeck Australia Pty Ltd, Novartis Pharmaceuticals Australia Pty Ltd, Pfizer Australia Pty Ltd, Bristol-Myers Squibb Pty Ltd, Sanofi-Aventis Australia Pty Ltd, Hospira Australia Pty Ltd, and AstraZeneca Pty Ltd. He is also a Trustee for the Psychosis Australia Trust and the Queensland Schizophrenia Research Foundation, and a board member of Clearthinking Queensland Ltd. 1 Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, et al.